- Epidemiology
-
Prognostic factors of pediatric hematopoietic stem cell transplantation recipients admitted to the pediatric intensive care unit
-
Da Hyun Kim, Eun Ju Ha, Seong Jong Park, Kyung-Nam Koh, Hyery Kim, Ho Joon Im, Won Kyoung Jhang
-
Acute Crit Care. 2021;36(4):380-387. Published online November 26, 2021
-
DOI: https://doi.org/10.4266/acc.2020.01193
-
-
5,294
View
-
103
Download
-
4
Web of Science
-
5
Crossref
-
Abstract
PDF
- Background
Pediatric patients who received hematopoietic stem cell transplantation (HSCT) tend to have high morbidity and mortality. While, the prognostic factors of adult patients received bone marrow transplantation were already known, there is little known in pediatric pateints. This study aimed to identify the prognostic factor for pediatric intensive care unit (PICU) mortality of critically ill pediatric patients with HSCT.
Method Retrospectively reviewed that the medical records of patients who received HSCT and admitted to PICU between January 2010 and December 2019. Mortality was defined a patient who expired within 28 days.
Results A total of 131 patients were included. There were 63 boys (48.1%) and median age was 11 years (interquartile range, 0–20 years). The most common HSCT type was haploidentical (38.9%) and respiratory failure (44.3%) was the most common reason for PICU admission. Twenty-eight–day mortality was 22.1% (29/131). In comparison between survivors and non-survivors, the number of HSCT received, sepsis, oncological pediatric risk of mortality-III (OPRISM-III), PRISM-III, pediatric sequential organ failure assessment (pSOFA), serum lactate, B-type natriuretic peptide (BNP) and use of mechanical ventilator (MV) and vasoactive inotropics were significant predictors (p<0.05 for all variables). In multivariate logistic regression, number of HSCT received, use of MV, OPRISM-III, PRISM-III and pSOFA were independent risk factors of PICU mortality. Moreover, three scoring systems were significant prognostic factors of 28-day mortality.
Conclusions The number of HSCT received and use of MV were more accurate predictors in pediatric patients received HSCT.
-
Citations
Citations to this article as recorded by 
- Outcomes within 100 days of hematopoietic cell transplantation in pediatric patients: insights from an intensive care unit in Colombia
Rubén E. Lasso-Palomino, Diego Medina, Alexis Antonio Franco, María José Soto-Aparicio, Eliana Manzi Tarapues, Diana Marcela Muñoz, Edgar Salazar, Jhon López, Angela Devia, Sofía Martínez-Betancur, Jimena Sierra, Anita V. Arias, Inés Elvira Gómez Frontiers in Pediatrics.2024;[Epub] CrossRef - Optimum Frequency for Physical Therapy Intervention in Pediatric Patients Undergoing Bone Marrow Transplantation in Acute Care Settings: A Systematic Review
Abigail Myers, Hallie Lenker, Rachel Reoli Rehabilitation Oncology.2024; 42(4): 164. CrossRef - Elevation of NT-proBNP Levels in Pediatric and Young Adult Hematopoietic Stem Cell Transplant Patients with Endotheliopathy
Kimberly Uchida, Xiaomeng Yuan, Jennifer McArthur, Rebekah Lassiter, Haitao Pan, Dinesh Keerthi, Katherine Tsai, Yvonne Avent, Melissa Hines, Hugo R. Martinez, Amr Qudeimat, Saad Ghafoor Pediatric Reports.2024; 16(4): 934. CrossRef - Prognostic factors and predictive scores for 6-months mortality of hematopoietic stem cell transplantation recipients admitted to the pediatric intensive care unit
Sarah Schober, Silke Huber, Norbert Braun, Michaela Döring, Peter Lang, Michael Hofbeck, Felix Neunhoeffer, Hanna Renk Frontiers in Oncology.2023;[Epub] CrossRef - Survival Outcomes of Pediatric Hematopoietic Stem Cell Transplant Patients Admitted to the Intensive Care Unit
Lujain Talib Aljudaibi, Mohamed Salaheldin Bayoumy, Hassan A. Altrabolsi, Abdullah M. Alzaydi, Nawaf Aldajani, Nadia Hammad, Ismail Alzahrani, Marwa Elhadidy, Ibraheem F. Abosoudah Journal of Applied Hematology.2022; 13(4): 192. CrossRef
|